|
Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer Clinical research trials and Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer. Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "H" Clinical Trials Conditions > Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer  Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer
Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer
For Condition: stage 2 prostate cancer,stage 3 prostate cancer,adenocarcinoma of the prostate
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Dana-Farber/Harvard Cancer Center
Synopsis: RATIONALE: Hyperthermia therapy may kill prostate cancer cells by heating them to several degrees above body temperature. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining hyperthermia with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of hyperthermia plus radiation therapy in treating patients who have nonmetastatic advanced prostate cancer.
Details: OBJECTIVES: I. Evaluate the efficacy of hyperthermia and radiation therapy in patients with locally advanced prostate cancer. II. Evaluate the acute and long term toxicities of these therapies in this patient population. PROTOCOL OUTLINE: Patients are treated with external beam irradiation 5 days a week for a total of approximately 7 weeks. Hyperthermia treatment is given twice in the first 4 weeks of radiation therapy, preferably early in the course of radiation. Hyperthermia treatments are only given once a week. A transrectal ultrasound applicator is used to deliver the hyperthermia treatment. Patients are followed every three months for 2 years, and every 6 months thereafter. PROJECTED ACCRUAL: Approximately 65 patients will be accrued over 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven prostate cancer; stage T2a, T2b, or T3a disease as defined by 1997 (current) AJCC criteria - No metastatic disease --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Up to 2 months of prior neoadjuvant hormonal therapy allowed Radiotherapy: No prior pelvic radiotherapy Surgery: Not specified Other: No anti-arrhythmic drugs --Patient Characteristics-- Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At least 5 years unless due to prostate cancer Hematopoietic: - WBC greater than 4000/mm3 - Platelet count greater than 100,000/mm3 - Hematocrit greater than 30% Hepatic: Not specified Renal: Not specified Cardiovascular: - No myocardial infarction within past 6 months - No unstable angina pectoris with medication - Diastolic BP no greater than 100 mm Hg - No pacemaker - No congestive heart failure requiring medication - No evidence of vasculopathy Neurologic: No evidence of neuropathy Pulmonary: No severe chronic obstructive pulmonary disease (FEV1 less than 50% of predicted or less than 1 liter) Other: - No prior or concurrent malignancy except nonmelanoma skin cancer - No severe, insulin dependent diabetes mellitus - No severe cerebrovascular disease
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MarkHurwitz, Study Chair, Dana-Farber/Harvard Cancer Center
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Joint Center for Radiation Therapy
Boston, Massachusetts, 02215
United States
Additional Information:
Study ID Numbers: CDR0000065679; DFCI-94153,NCI-H97-1294
Study Start Date: April 1997
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003045
Other Stage 3 Prostate Cancer Studies:
1. TG4010 in Treating Patients With Prostate Cancer
2. Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
3. Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer
4. Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
5. Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer
Related Studies:
Other stage 3 prostate cancer Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer
|
|
|
|
|
|
|
|
